These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38226446)

  • 1. [Empagliflozin: current indications and aspects for daily clinical practice].
    Iacoviello M; Aspromonte N
    G Ital Cardiol (Rome); 2023 Dec; 24(12 Suppl 3):3S-12S. PubMed ID: 38226446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
    Rao VS; Ivey-Miranda JB; Cox ZL; Moreno-Villagomez J; Maulion C; Bellumkonda L; Chang J; Field MP; Wiederin DR; Butler J; Collins SP; Turner JM; Wilson FP; Inzucchi SE; Wilcox CS; Ellison DH; Testani JM
    J Am Soc Nephrol; 2024 Feb; 35(2):189-201. PubMed ID: 38073038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Empagliflozin in the elderly].
    Berrut G; Boureau AS; Trochu JN; Genet B; de Decker L; Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2021 Jun; 19(2):137-147. PubMed ID: 34165436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
    Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Forman JL; Møller JE; Schou M
    Circulation; 2021 Jun; 143(22):2208-2210. PubMed ID: 34061581
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    Packer M; Anker SD; Butler J; Filippatos G; Pocock SJ; Carson P; Januzzi J; Verma S; Tsutsui H; Brueckmann M; Jamal W; Kimura K; Schnee J; Zeller C; Cotton D; Bocchi E; Böhm M; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Janssens S; Zhang J; Gonzalez Juanatey JR; Kaul S; Brunner-La Rocca HP; Merkely B; Nicholls SJ; Perrone S; Pina I; Ponikowski P; Sattar N; Senni M; Seronde MF; Spinar J; Squire I; Taddei S; Wanner C; Zannad F;
    N Engl J Med; 2020 Oct; 383(15):1413-1424. PubMed ID: 32865377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction.
    Chilton R
    Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
    [No Abstract]   [Full Text] [Related]  

  • 12. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Packer M
    Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
    [No Abstract]   [Full Text] [Related]  

  • 13. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.
    Philippaert K; Kalyaanamoorthy S; Fatehi M; Long W; Soni S; Byrne NJ; Barr A; Singh J; Wong J; Palechuk T; Schneider C; Darwesh AM; Maayah ZH; Seubert JM; Barakat K; Dyck JRB; Light PE
    Circulation; 2021 Jun; 143(22):2188-2204. PubMed ID: 33832341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
    Kokhan E; Kiyakbaev G; Medovchshikov V
    Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
    [No Abstract]   [Full Text] [Related]  

  • 16. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
    Chen S; Wang Q; Christodoulou A; Mylonas N; Bakker D; Nederlof R; Hollmann MW; Weber NC; Coronel R; Wakker V; Christoffels VM; Andreadou I; Zuurbier CJ
    Circulation; 2023 Jan; 147(3):276-279. PubMed ID: 36649392
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.
    Liang B; Gu N
    Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.